UC Davis, TargaGenix, Northeastern University receive $3M R01 grant to study pancreatic cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A partnership between UC Davis Comprehensive Cancer Center, TargaGenix, and Northeastern University will receive nearly $3 million over five years to study pancreatic ductal adenocarcinoma through an NIH R01 grant. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Researchers at Moffitt Cancer Center have published a case study highlighting the potential optimization of the TAMP, or trans-arterial micro-perfusion, procedure with RenovoCath to deliver intra-arterial gemcitabine (a commonly used chemotherapy) directly near a tumor (rather than traditional systemic IV administration) in a patient with locally advanced pancreatic cancer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login